Mark E Anderson Selected Research

Calmodulin (Calcium-Dependent Activator Protein)

1/2017	CaMKII is a nodal signal for multiple programmed cell death pathways in heart.
1/2016	Exercise training prevents ventricular tachycardia in CPVT1 due to reduced CaMKII-dependent arrhythmogenic Ca2+ release.
1/2016	Calmodulin/CaMKII inhibition improves intercellular communication and impulse propagation in the heart and is antiarrhythmic under conditions when fibrosis is absent.
12/2012	CaMKII inhibition rescues proarrhythmic phenotypes in the model of human ankyrin-B syndrome.
6/2011	Is CaMKII a link between inflammation and hypertrophy in heart?
3/2011	The multifunctional Ca2+/calmodulin-dependent kinase II delta (CaMKIIdelta) controls neointima formation after carotid ligation and vascular smooth muscle cell proliferation through cell cycle regulation by p21.
8/2010	Ca2+/calmodulin-dependent kinase IIdelta causes heart failure by accumulation of p53 in dilated cardiomyopathy.
5/2009	CaMKII and a failing strategy for growth in heart.
4/2005	Calmodulin kinase signaling in heart: an intriguing candidate target for therapy of myocardial dysfunction and arrhythmias.
2/2002	Calmodulin inhibitor W-7 unmasks a novel electrocardiographic parameter that predicts initiation of torsade de pointes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark E Anderson Research Topics

Disease

27	Heart Failure 01/2022 - 06/2008
19	Cardiac Arrhythmias (Arrythmia) 01/2022 - 01/2002
13	Hypertrophy 01/2019 - 04/2005
12	Heart Diseases (Heart Disease) 01/2017 - 04/2005
11	Atrial Fibrillation 01/2021 - 07/2005
11	Myocardial Infarction 01/2020 - 04/2005
10	Inflammation (Inflammations) 01/2019 - 06/2011
9	Cardiomyopathies (Cardiomyopathy) 04/2014 - 01/2002
8	Ventricular Tachycardia 01/2021 - 08/2006
8	Cardiovascular Diseases (Cardiovascular Disease) 03/2013 - 08/2006
7	Cardiac Sudden Death (Sudden Cardiac Arrest) 01/2022 - 12/2005
6	Ischemia 01/2019 - 12/2005
6	Fibrosis (Cirrhosis) 01/2019 - 05/2012
6	Asthma (Bronchial Asthma) 12/2017 - 06/2004
6	Sudden Death 01/2014 - 04/2007
5	Polymorphic catecholergic ventricular tachycardia 01/2021 - 08/2006
5	Sick Sinus Syndrome 08/2014 - 10/2008
5	Cardiomegaly (Heart Hypertrophy) 01/2014 - 01/2002
4	Neoplasms (Cancer) 12/2015 - 03/2013
3	Atrial Remodeling 01/2019 - 05/2012
3	Reperfusion Injury 01/2016 - 11/2012
3	Vascular System Injuries 02/2014 - 03/2011
3	Hypertension (High Blood Pressure) 02/2012 - 02/2010
2	Death (Near-Death Experience) 01/2022 - 09/2006
2	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 01/2020 - 08/2010
2	Disease Progression 01/2019 - 01/2013
2	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 01/2018 - 04/2013
2	Congenital Heart Defects (Congenital Heart Defect) 10/2017 - 10/2003
2	Hyperglycemia 01/2017 - 01/2014
2	Lung Diseases (Lung Disease) 01/2017 - 12/2015
2	Hyperplasia 02/2014 - 03/2011
2	Bradycardia 01/2014 - 11/2010
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2014 - 10/2009
2	Heart Rupture 01/2014 - 11/2011
2	Ankyrin-B-Related Cardiac Arrhythmia 05/2013 - 12/2012
2	Cardiotoxicity 03/2013 - 11/2011
2	Left Ventricular Dysfunction 03/2013 - 09/2006
2	Infarction (Infarctions) 11/2012 - 12/2009
2	Neointima 05/2012 - 03/2011
2	Tachycardia (Tachyarrhythmias) 05/2007 - 10/2003
2	Sudden Infant Death (SID) 04/2007 - 01/2005
2	Long QT Syndrome 10/2005 - 03/2004
1	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 01/2019
1	Nasal Polyps (Nasal Polyp) 01/2018
1	Rhinosinusitis 01/2018
1	Polyps 01/2018
1	Respiratory Hypersensitivity 12/2017
1	Eosinophilia 01/2017
1	Prediabetic State (Prediabetes) 01/2016

Drug/Important Bio-Agent (IBA)

59	Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA 01/2021 - 01/2002
24	Calcium-Calmodulin-Dependent Protein KinasesIBA 01/2020 - 01/2002
16	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019 - 12/2005
14	Proteins (Proteins, Gene)FDA Link 04/2016 - 09/2006
10	Calmodulin (Calcium-Dependent Activator Protein)IBA 01/2017 - 02/2002
9	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA 01/2021 - 08/2006
9	CalciumIBA 12/2018 - 08/2006
6	Phosphotransferases (Kinase)IBA 01/2017 - 05/2009
6	Ion Channels (Ion Channel)IBA 10/2013 - 10/2005
6	AnkyrinsIBA 05/2013 - 10/2008
5	Adenosine Triphosphate (ATP)IBA 01/2022 - 09/2007
5	Peptides (Polypeptides)IBA 01/2019 - 02/2010
5	Oxidants (Oxidizing Agents)IBA 01/2018 - 08/2011
4	Adrenergic Agents (Adrenergic Drugs)IBA 01/2017 - 12/2006
4	Pharmaceutical PreparationsIBA 01/2017 - 08/2006
4	Angiotensin IIIBA 05/2012 - 02/2010
3	Isoproterenol (Isoprenaline)FDA LinkGeneric 01/2021 - 12/2006
3	AllergensIBA 12/2017 - 07/2013
3	AntioxidantsIBA 01/2017 - 03/2013
3	SpectrinIBA 04/2016 - 10/2013
3	Membrane Proteins (Integral Membrane Proteins)IBA 05/2012 - 07/2010
2	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2021 - 06/2012
2	CalpainIBA 12/2018 - 08/2012
2	Peptide Hydrolases (Proteases)FDA Link 12/2018 - 08/2012
2	Immunoglobulin E (IgE)IBA 01/2018 - 12/2017
2	KN 93IBA 12/2017 - 02/2010
2	CytokinesIBA 01/2017 - 01/2015
2	KATP ChannelsIBA 01/2016 - 12/2011
2	junctophilinIBA 04/2014 - 08/2010
2	Potassium Channels (Potassium Channel)IBA 04/2014 - 07/2005
2	EnzymesIBA 08/2013 - 11/2011
2	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2013 - 11/2011
2	AldosteroneIBA 01/2013 - 11/2011
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 12/2012 - 09/2006
2	Methionine Sulfoxide ReductasesIBA 11/2011 - 05/2008
2	CatecholaminesIBA 11/2011 - 08/2006
2	Caffeine (No Doz)FDA LinkGeneric 12/2010 - 08/2006
2	Epinephrine (Adrenaline)FDA LinkGeneric 12/2010 - 08/2006
2	SmokeIBA 04/2007 - 01/2005
2	Protein Kinases (Protein Kinase)IBA 08/2006 - 04/2005
1	Phosphorus (Red Phosphorus)IBA 01/2022
1	Diltiazem (Cardizem)FDA LinkGeneric 01/2019
1	Tryptophan Oxygenase (Tryptophan 2,3 Dioxygenase)IBA 01/2018
1	KynurenineIBA 01/2018
1	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 01/2018
1	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 01/2018
1	InflammasomesIBA 01/2017
1	Connexin 43 (Connexin43)IBA 01/2016
1	salicylhydroxamic acid (SHAM)IBA 01/2016

Therapy/Procedure

14	Therapeutics 01/2019 - 06/2004
2	Ligation 05/2012 - 03/2011